Who Generates Higher Gross Profit? Halozyme Therapeutics, Inc. or Amneal Pharmaceuticals, Inc.

Amneal vs. Halozyme: Gross Profit Battle Unveiled

__timestampAmneal Pharmaceuticals, Inc.Halozyme Therapeutics, Inc.
Wednesday, January 1, 201444963400052602000
Thursday, January 1, 2015499226000105812000
Friday, January 1, 2016597455000113485000
Sunday, January 1, 2017526178000285461000
Monday, January 1, 2018716403000141726000
Tuesday, January 1, 2019352997000150446000
Wednesday, January 1, 2020628393000224227000
Friday, January 1, 2021768973000361897000
Saturday, January 1, 2022784708000520812000
Sunday, January 1, 2023820565000636892000
Monday, January 1, 2024855907000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Companies: Gross Profit Showdown

In the competitive landscape of pharmaceuticals, understanding who leads in profitability can offer valuable insights. Over the past decade, Amneal Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc. have been vying for dominance in gross profit generation. From 2014 to 2023, Amneal consistently outperformed Halozyme, with an average gross profit nearly 2.4 times higher. However, Halozyme has shown remarkable growth, increasing its gross profit by over 1,100% from 2014 to 2023. In 2023, Halozyme's gross profit reached 78% of Amneal's, narrowing the gap significantly. This trend highlights Halozyme's aggressive growth strategy and its potential to challenge Amneal's long-standing lead. As the pharmaceutical industry evolves, these two companies exemplify the dynamic shifts in market leadership and profitability.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025